2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Factor XI
  5. Factor XI Inhibitor

Factor XI Inhibitor

Factor XI Inhibitors (13):

Cat. No. Product Name Effect Purity
  • HY-156613
    Frunexian
    		Inhibitor
    Frunexian (EP-7041) is a selective and potent inhibitor of coagulation factor XI/activated factor XI, targeting to factor XIa. Frunexian exhibits antithrombotic activity, with no bleeding liability in rat mesenteric arterial puncture model. Frunexian can be used in extracorporeal membrane oxygenation (ECMO) research.
  • HY-134005
    ISIS 416858
    		Inhibitor
    ISIS 416858, a single-stranded antisense oligodeoxynucleotide, is a potent and selective inhibitor of FXI mRNA expression.
  • HY-177669
    Vortosiran
    		Inhibitor
    Vortosiran, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.
  • HY-117290A
    BMS-962212 hydrochloride
    		Inhibitor
    BMS-962212 hydrochloride is a selective coagulation factor XIa inhibitor and acute antithrombotic agent. BMS-962212 hydrochloride can be used in the research of thrombosis.
  • HY-177669B
    Vortosiran sodium scrambled negative control
    		Inhibitor
    Vortosiran sodium scrambled negative control is the sequence scrambled negative control of Vortosiran sodium.
  • HY-160824
    Neutrophil elastase-IN-7
    		Inhibitor
    Neutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC50 value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC50 values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.
  • HY-P991581
    MK-2060
    		Inhibitor ≥99.0%
    MK-2060 is a humanized monoclonal antibody inhibitor targeting FXI. MK-2060 can be used for atherothrombosis and venous thromboembolism research.
  • HY-177669A
    Vortosiran sodium
    		Inhibitor
    Vortosiran sodium, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.
  • HY-172400
    FXIa-IN-16
    		Inhibitor
    FXIa-IN-16 (Compound 43) is an orally active and selective Factor XIa (FXIa) inhibitor with an IC50 of 0.19 nM. FXIa-IN-16 exhibits strong anticoagulant and antithrombotic activities and shows good safety in mice. FXIa-IN-16 can be used in the research related to the treatment of thrombosis.
  • HY-143477
    Factor XI-IN-1
    		Inhibitor
    Factor XI-IN-1 (Compound 27) is a factor XI activation inhibitor with an EC50 of 25.14 nM.
  • HY-150519
    FXIa/Plasma kallikrein-IN-1
    		Inhibitor
    FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with Ki values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases.
  • HY-180223
    FXIa-IN-17
    		Inhibitor
    FXIa-IN-17 (Compound FE12) is a selective FXIa inhibitor with an IC50 of 4.4 nM. FXIa-IN-17 effectively inhibits thrombus formation.
  • HY-175735
    Factor XI-IN-2
    		Inhibitor
    Factor XI-IN-2 is a Factor XI activation inhibitor with an IC50 of 20 nM. Factor XI-IN-2 does not directly inhibit the enzymatic activity of FXIa, but specifically binds to the FXI enzyme precursor and allosterically inhibits the process by which it is activated by FXIIa. Factor XI-IN-2 inhibits thrombosis in the rabbit arteriovenous (AV) shunt thrombosis model. Factor XI-IN-2 can be used for the study of antithrombus.